Synthesis of new biologically active compounds containing linked thiazolyl-thiazolidinone heterocycles by Nagaraj Adki et al.
ORIGINAL ARTICLE      
 
 
The article was published by Academy of Chemistry of Globe Publications 
www.acgpubs.org/OC/index.htm © Published 11/27/2012 EISSN:1307-6175 
 
 
 
 
 
 
Org. Commun. 5:4 (2012) 160-170 
 
 
Synthesis of new biologically active compounds containing linked 
thiazolyl-thiazolidinone heterocycles 
 
Nagaraj Adki
*, Ravi G, Naseem, Sharath Kumar S and Nageswara Rao G 
 
 
Department of Pharmaceutical Chemistry, Telangana University, Nizamabad 503 322, India 
 
(Received November 8, 2011; Revised August 11, 2012; Accepted August 11, 2012) 
 
 
Abstract: A new series of 1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one 5a-j has been synthesized by the reaction 
of  2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one  4  with 
aryl aldehydes. Chemical structures of all the new compounds were established by IR, 
1H, 
13C NMR, MS and 
elemental  data.  The  compounds  5a-j  were  evaluated  for  their  antibacterial  activity  against  Gram-positive 
bacteria viz. Bacillus subtilis (MTCC 441), Bacillus sphaericus (MTCC 11), Staphylococcus aureus (MTCC 96) 
and  Gram-negative  bacteria  viz.  Pseudomonas  aeruginosa  (MTCC  741),  Klebsiella  aerogenes  (MTCC  39), 
Chromobacterium violaceum  (MTCC 2656).  Amongst them, compounds containing [(4-chlorophenyl)methyli- 
dene]  moiety  5b,  [(3-nitrophenyl)methylidene]  moiety  5d  and  [(2-thienyl)methylidene]  moiety  5j  showed 
significant antibacterial activity, almost equal/more than the activity of the standard drug Streptomycin.  Further, 
the compounds 5a-j were also screened for their antifungal activity against Candida albicans (ATCC 10231), 
Aspergillus fumigatus (HIC 6094), Trichophyton rubrum (IFO 9185), and Trichophyton mentagrophytes (IFO 
40996).  Most of these new compounds showed appreciable activity against test bacteria and fungi and emerged 
as potential molecules for further development.  
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1. Introduction  
 
Heterocyclic compounds represent one of the most active classes of compounds possessing a 
wide  spectrum  of  biological  activities,  including  antibacterial,  antifungal,  and  other  biological 
activities.
1-6 Further, the treatment of infectious diseases still remains an important and challenging 
problem because of a combination of factors including emerging infectious diseases and the increasing 
number of multi-drug resistant microbial pathogens. In spite of a large number of antibiotics and 
chemotherapeutics available for medical use, at the same time the emergence of old and new antibiotic 
resistance created in the last decades revealed a substantial medical need for new classes of antimicro- 
bial  agents.    There  is  a  real  perceived  need  for  the  discovery  of  new  compounds  endowed  with 
antimicrobial activity.  Similarly in recent decades, an increased incidence of fungal infections has 
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been observed as a consequence of the growing number of immunocompromised patients and the 
frequent  use  of  antibacterial  and  cytotoxic  drugs.  For  many  fungal  infections,  polyenes,  such  as 
amphotericin  B,  represent  the  standard  therapy.  Polyenes  bind  to  membrane  sterols,  leading  to 
membrane permeability, leakage and cell death. However, the clinical use of amphotericin B is limited 
by a high frequency of renal toxicity, and several adverse effects.
7 Though the various molecules 
designed and synthesized for the above aim and to reduce the adverse effects, it was demonstrated that 
thiazoles  and  its  derivatives  offer  several  advantages  in  terms  of  decreased  toxicity  after  oral  or 
intravenous
8 administration and are often employed in the treatment of fungal infections, therefore the 
thiazoles and its derivatives could be considered as possible antimicrobial agents.
9 
Further, the thiazole nucleus appears frequently in the structure of various natural products and 
biologically  active  compounds,  notably  thiamine  (vitamin-B),    antibiotics  such  as  penicillin, 
micrococcin
10, troglitazone
11 and many metabolic products of fungi and primitive marine animals, 
including  2-(aminoalkyl)thiazole-4-carboxylic  acids.
12    Similarly,  there  has  been  a  considerable 
interest in the chemistry of thiazolidin-4-one ring system, which is a core structure in various synthetic 
pharmaceuticals displaying a broad spectrum of biological activities.
13 Thiazolidinone ring also occurs 
in nature; thus actithiazic acid isolated from Streptomyces strains exhibits highly specific in vitro 
activity against Mycobacterium tuberculosis
14. Thiazolidinone derivatives are also known to exhibit 
diverse bioactivities such as anti-convulsant
15, antidiarrheal
16, anti-platelet activating factor
17, anti-
histaminic
18,  anti-diabetic
19,  cyclooxy  genase  (COX)  inhibitory
20,
  Ca
2+-channel  blocker
21,  platelet 
activating factor (PAF) antagonist
22, cardioprotective
23, anti-ischemic
24, anti-cancer
25, tumor necrosis 
factor-α  antagonist
26  and  nematicidal  activities.
27  The  synthesis  of  heterocycles  containing  multi-
structure in  a  molecule  has  received  much  attention  in  recent  years
28.  However,  literature  survey 
revealed that linked heterocycles containing thiazole and thiazolidinone have seldom been reported. 
Based on the wide spectum of biological profile of thiazole and thiazolidin-4-one and their 
increasing importance in pharmaceutical, and biological field, and in continuation of our on going 
research on biologically active heterocycles,
29,30 it was thought of interest to accommodate thiazole 
and thiazolidin-4-one moieties in a single molecular frame work to synthesize some new heterocyclic 
compounds with potential biological activity. 
The present investigation deals with the synthesis of some new 1,3-benzothiazol-2-yl)-1,3-
thiazolan-4-one  5a-j in  good  yields,  from  2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,5,6,7-tetrahydro-
1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one  4.  The  antibacterial  and  antifungal  activities  of  the 
compounds 5a-j have also been evaluated. 
 
 
2. Results and Discussion  
Cyclocondensation of compound 1 with thiaourea in the presence of iodine in ethanol at reflux 
for 6 h, gave 5,5,7-trimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine 2 in 62% yield.
31 Further, 
condensation of compound 2 with p-methylbenzaldehyde in acetic acid at reflux for 3 h, afforded N-
[(E)-1-(4-methylphenyl)methyldene]-N-(5,5,7-trimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl 
)amine  3  in  64%  yield.  The  one-pot  synthesis  of  2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,5,6,7-
tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one  4  was  carried  out  by  the  condensation-
cyclization  reaction  between  compound  3  and  mercaptoacetic  acid  in  the  presence  of  ZnCl2  in 
dimethylformamide solvent under reflux for 6 h. Further, compounds 4 on condensation with aromatic 
aldehydes in the presence of anhydrous NaOAc in glacial AcOH at reflux temperature for gave 1,3-
benzothiazol-2-yl)-1,3-thiazolan-4-one  5a-j  in  62-72%  yields  (Scheme  1).    The  versatility  of  the 
reaction is well demonstrated by the fact that a variety of aromatic aldehydes with electron-releasing 
and electron-withdrawing substituents afforded their corresponding compounds 5a-j in good yields. 
The structures of all the newly synthesized compounds were confirmed by elemental analysis, IR, 
1H 
NMR, 
13C NMR and MS spectral data. 
In the IR spectra of compounds 5a–j, the amide carbonyl (C=O) and conjugated double bond 
(C=C) absorption bands were observed at 1698 and 1614 cm
-1 respectively, confirm the condensation 
involving the methylene group and the aldehyde system.  Further, support was obtained from the 
1H 
NMR  spectra,  the  disappearence  of  the  signal  corresponding  to  the  CH2-S  protons  at  3.71  ppm 
indicated  the  condensation  with  carbonyl  group.    The  N–CH–S  proton  of  thiazolidin-4-one  ring Nagaraj et al., Org. Commun. (2012) 5:4 160-170 
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appeared at 6.62 ppm, the other aromatic and aliphatic protons appeared at the expected regiod.  In the 
13C NMR spectra, the prominent signals corresponding to the carbons of thiazolidin-4-one ring in all 
the compounds observed nearly at 161.0, 141.3 and 71.8 ppm, are proof of further evidence of their 
structures.  In summary, all the synthesized compounds exhibited satisfactory spectral data consistent 
with their structures. 
 
5: Ar  =   (a) 4-CH3-C6H4;   (b) 4-Cl-C6H4;   (c) 4-NO2-C6H4;   (d) 3-NO2-C6H4;   (e) 4-OH-C6H4;   (f) 2-OH-C6H4;           
(g) 4-(CH3)2N-C6H4 ;  (h) 4-(OH)-3-CH3O)-C6H3; (i) 2-furyl;   (j) 2-thienyl         
 
Scheme 1. Synthetic pathways for compounds  5a-j 
 
 
2.1. Antibacterial Activity 
 
All  the  compounds  6a-j  were  assayed  for  their  antibacterial  activity  against  three 
representative Gram-positive bacteria viz. Bacillus subtilis (MTCC 441), Bacillus sphaericus (MTCC 
11), Staphylococcus aureus (MTCC 96) and Gram-negative bacteria viz. Pseudomonas aeruginosa 
(MTCC 741), Klebsiella aerogenes (MTCC 39), Chromobacterium violaceum  (MTCC 2656) by disc 
diffusion method,
32 and the mean inhibition zone data are reported in Table 1.
   All assays included the 
solvent and reference controls.  Streptomycin was used as standard drug. 
The investigation of antibacterial screening data reveal that almost all the compounds 5a-j are 
active and showing moderate to good antibacterial activity. Amongst them, compounds containing [(4-
chlorophenyl)methylidene]  moiety  5b,  [(3-nitrophenyl)methylidene]  moiety  5d  and  [(2-thienyl) 
methylidene] moiety 5j showed significant antibacterial activity, almost equal/more than the activity 
of  the  standard  drug  Streptomycin.    Further,  compounds  5b,  5d  and  5j  were  active  against  P. 
aeruginosa, compounds 5b, 5j were active against C. violaceum (Table 1 and 2).  The remaining 
compounds showed moderate to good activity. 
 
 
 
2.2. Antifungal Activity 
 
  The compounds 5a-j were also screened for their antifungal activity against Candida albicans 
(ATCC  10231),  Aspergillus  fumigatus  (HIC  6094),  Trichophyton  rubrum  (IFO  9185),  and 
Trichophyton mentagrophytes (IFO 40996) in dimethyl sulfoxide (DMSO) by disc difusion method.
32   
Amphotericin B was used as a standard drug and the mean inhibition zone (MZI) data were measured 
and compared with controls, the MZI values of the compounds screened are given in Table 2. 
  The antifungal screening data showed appreciable activity of the test compounds. Among the 
screened  compounds,  compound  5b  is  highly  active  against  T.  rubrum  and  T.  mentagrophytes, 
compound 5d is also active against C. albicans and compound 5j is highly active against C. albicans 
and  T.  mentagrophytes,  the  activity  of  these  compounds  are  almost  equal  to  the  standard.  It  is       Biologically active compounds containing linked thiazolyl-thiazolidinone heterocycles 
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interesting to note that the compounds 5d and 5j showed good antifungal activity towards C. albicans 
which is more than the activity of standard drug. 
 
Table 1. Antibacterial Activity of Compounds 5a-j 
Compound    Mean zone inhibition (MZI)
a in 100 µg/mL 
  B. subtilis  B. sphaericus  S. aureus  P. aeruginosa  K. aerogenes  C. violaceum 
6a  19  15  29  15  20  17 
6b  29  20  28  17  24  21 
6c  16  18  24  12  17  17 
6d  31  24  31  16  25  19 
6e  15  18  20  12  22  17 
6f  25  12  21  10  22  11 
6g  18  16  11  14  19  19 
6h  20  20  26  16  24  21 
6i  22  23  19  12  22  16 
6j  27  25  28  20  22  21 
Streptomycin  30  20  31  15  25  20 
 
aValues are mean (n = 3). 
 
Table 2. Antifungal Activity of Compounds 5a-j 
 
Compound  Mean zone inhibition (MZI)
a in 100 µg/mL 
  C. albicans  A. fumigatus  T. rubrum  T. mentagropytes 
5a  16  18  12  19 
5b  24  22  17  23 
5c  16  20  18  18 
5d  21  25  18  23 
5e  14  20  17  20 
5f  12  19  13  19 
5g  13  13  16  20 
5h  20  22  17  12 
5i  14  14  18  20 
5j  24  24  22  22 
Amphotericin B  22  25  20  22 
aValues are mean (n = 3). 
 
3. Conclusions 
  
A  new  series  of  1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one  5a-j  has  been  synthesized  and 
evaluated for their antimicrobial activity against Gram-positive, Gram-negative bacterial and fungi. 
Most  of  the  compounds  showed  a  moderate  degree  of  antimicrobial  activity.  Amongst  them, 
compounds  containing  [(4-chlorophenyl)methylidene]  moiety  5b,  [(3-nitrophenyl)methylidene] 
moiety 5d and [(2-thienyl) methylidene] moiety 5j showed significant antibacterial activity, almost 
equal/more than the activity of the standard drug streptomycin. Further, these compounds showed 
appreciable  activity  against  the  test  fungi,  and  emerged  as  potential  molecules  for  further 
development. 
 
4. Experimental 
 
Reagents were of commercial grade and were used as supplied or were prepared according to 
procedures described in literature. Reactions were monitored by thin-layer chromatography (TLC) on Nagaraj et al., Org. Commun. (2012) 5:4 160-170 
 
164
pre-coated silica gel F254 plates from Merck, and compounds visualized either by exposure to UV 
light. Chromatographic columns 70–230 mesh silica gel for separations were used. Melting points 
were determined on a Fisher–Johns apparatus and are uncorrected. IR spectra were recorded using 
KBr disk on a Perkin–Elmer FTIR spectrometer.  The 
1H NMR, 
13C NMR spectra were recorded on a 
Varian Gemini spectrometer (300 MHz for 
1H and 75 MHz for 
13C).  Chemical shifts are reported in δ 
ppm units with respect to TMS as internal standard and coupling constants (J) are reported in Hz units.  
Mass spectra were recorded on a VG micro mass 7070H spectrometer. Elemental analyses (C, H, N) 
determined by means of a Perkin–Elmer 240 CHN elemental analyzer, were within ± 0.4% of theory. 
 
 
4.1. Synthesis of 5,5,7-trimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine (2):  
 
 
To a solution of compound 1 (1.4g, 0.01 mol) in ethanol (10 mL), thiourea (1.52g, 0.02 mol) 
and iodine (2.54 g, 0.01 mol) were added and the reaction mixture was heated under reflux for 6 hrs.  
The reaction mixture was then cooled to 20 
oC and quenched in water (50 mL). The quenched mass 
was basified with liquor ammonia solution and extracted with ethyl acetate (100 mL).  The ethyl 
acetate extract was then concentrated and the crude residue was purified by column chromatography 
using  chloroform  as  eluent  and  silicagel  (70-230  mesh)  as  solid  phase.    The  pure  fraction  on 
concentration gave the pure compound 2 in 62% of yield,  Pale white solid m.p. 55-57
 oC; IR (KBr): 
ν 3480-3275, 2953, 2877, 1562, 758 cm
-1; 
1H NMR (CDCl3): δ 0.94 (s, 6H, CH3), 1.27-1.29 (d, J = 6.7 
Hz, 3H, CH3), 1.30-1.40 (quasi d, J = 4.6 Hz, 2H, CH2), 2.07 (s, 2H, CH2), 2.41-2.45 (m, 1H, CH), 
4.96 (bs, 2H, NH2); 
 13C NMR (CDCl3): δ 21.7, 28.5 (2 x CH3), 31.3, 36.4, 47.0, 47.7, 128.6, 139.4, 
156.5; MS: m/z (%) 197 (M
++1, 33), 180 (100), 166 (47).  Anal. Calcd. for C10H16N2S: C, 61.18; H, 
8.21; N, 14.27.  Found: C, 61.14; H, 8.22; N, 14.20. 
 
4.2. Synthesis of N-[(E)-1-(4-methylphenyl)methyldene]-N-(5,5,7-trimethyl-4,5,6,7-tetrahydro- 1,3-
benzothiazol-2-yl)amine (3):  
 
 
A mixture of compound 3 (1.96 g, 0.01 mol), 4-methylbenzaldehyde (1.2 mL, 0.01 mol) and 
acetic acid (0.5 mL) was refluxed in toluene for 3 h using a Dean-stark apparatus and the water formed 
was removed azeiotropically.  The progress of the reaction was checked by TLC using toluene: ethyl 
acetate (4:1) as an eluent.  After completion of the reaction, solvent was removed by distillation to 
give solid, which was filtered, and recrystallized from ethyl alcohol to give pure compound 4 in 64% 
of yield, Dark yellow solid  m.p. 136-138 
oC; IR (KBr): ν 3052, 2988, 1625, 1610 cm
-1; 
1H NMR 
(DMSO-d6): δ 0.94 (s, 6H, CH3), 1.27-1.30 (d, J = 6.7 Hz, 3H, CH3), 1.40-1.45 (quasi d, J = 4.6 Hz, 
2H, CH2), 2.08 (s, 2H, CH2), 2.20 (s, 3H, CH3), 2.24-2.30  (m, 1H, CH), 7.00 (d, J = 7.2 Hz, 2H, ArH), 
7.50 (d, J = 7.2 Hz, 2H, ArH), 8.20 (s, 1H, CH=N);  
13C NMR (DMSO-d6): δ 19.0, 22.4, 26.4, 26.9 (2 
x CH3), 36.2, 43.8, 47.8, 122.4, 128.3 (2 x CHAr), 129.0 (2 x CHAr), 136.7, 140.6, 141.1, 160.0, 
162.5; MS: m/z (%) 298 (M
+, 71), 195 (23), 180 (100), 104 (63). Anal. Calcd for C18H22N2S: C, 72.44; 
H, 7.43; N, 9.39.  Found: C, 72.40; H, 7.39; N, 9.32. 
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4.3.  Synthesis  of  2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-  2-yl)-
1,3-thiazolan-4-one (4):   
 
 
A mixture of compound 3 (2.98g, 0.01 mol), thioglycolic acid (2.5 mL, 0.022 mol) in N, N-
dimethylformamide (20 mL) with a pinch of anhydrous ZnCl2, was refluxed for 6 h, the progress of 
the reaction was checked by TLC using toluene: ether (3:1) as an eluent. The reaction mixture was 
cooled to room temperature and then poured into crussed ice. It was set-aside at room temperature 
overnight. The solid thus separated was filtered, washed several times with water, and purified by 
column chromatography on silica-gel with hexane-ethyl acetate as eluent to afford pure compound 5 in 
62% yield; Brown solid  m.p. 147-149 
oC; IR (KBr): ν 3062, 1698, 1612, 1604, 1475 cm
-1; 
1H NMR 
(DMSO-d6): δ
  0.94 (s, 6H, CH3), 1.27-1.30 (d, J = 6.6 Hz, 3H, CH3), 1.40-1.45 (quasi d, J = 4.6 Hz, 
2H, CH2), 2.20 (s, 2H, CH2), 2.29 (s, 3H, CH3), 2.50-2.55 (m, 1H, CH), 3.71 (s, 2H, CH2-S), 5.90 (s, 
1H, CH-S), 7.10-7.20 (m, 4H, ArH); 
13C NMR (DMSO-d6): δ 19.2, 22.7 (2x CH3), 27.8, 28.1, 34.7, 
35.2, 42.3, 45.8, 73.1, 125.1, 126.4 (2 x CHAr), 127.6 (2 x CHAr), 133.4, 134.6, 139.0, 146.8, 173.4; 
MS: m/z (%) 372 (M
+, 100), 281 (46), 331 (17), 180 (28). Anal. Calcd for C20H24N2OS2: C, 64.48; H, 
6.49; N, 7.52. Found: C, 62.42; H, 6.43; N, 7.50. 
 
 
4.4.  General  procedure  for  the  synthesis  of  1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one  (5a-j):  A 
mixture of compound 4 (3.72g, 0.01 mol), corresposnding aldehyde (0.01 mol) and sodium acetate 
(0.02 mol) in anhydrous glacial acetic acid (10 mL), was refluxed for 6 h. The reaction mixture was 
concentrated and then poured into ice cold water, the solid thus separated, was filtered, washed with 
water, the crude product thus obtained was purified by column chromatography on silica gel with 
hexane-ethyl acetate as eluent to afford pure compounds 5a-jin 68-74% yields. All the products were 
characterized by IR, 
1H, 
13C NMR, MS and elemental analyses. 
 
 
4.4.1.  2-(4-methylphenyl)-5-[(Z)-1-(4-methylphenyl)methylidene]-3-(5,5,7-trimethyl-4,5,6,7- 
tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5a):  
 
 
Yield 62%, Yellow solid, m.p. 156-158 
oC; IR (KBr): ν 3067, 2974, 1698, 1614, 1604, 1477 cm
-1; 
1H 
NMR (DMSO-d6): δ
 0.94 (s, 6H, CH3), 1.20-1.25 (d, J = 6.7 Hz, 3H, CH3), 1.52-1.55 (quasi d, J = 4.6 
Hz, 2H, CH2), 2.09 (s, 2H, CH2), 2.35 (s, 3H, CH3), 2.42 (s, 3H, CH3), 2.60-2.65 (m, 1H, CH), 6.62 (s, 
1H, CH-S), 7.10-7.30 (m, 6H, ArH), 7.52 (d, J = 7.6 Hz, 2H, ArH), 7.70 (s, 1H, CH=C); 
13C NMR 
(DMSO-d6): δ 18.5, 22.7, 23.2, 26.8, 29.1 (2 x CH3), 36.7, 42.1, 45.7, 71.8, 126.3 (2 x CHAr), 127.0, 
128.9, 129.0 (2 x CHAr), 129.7, 130.4 (2 x CHAr), 131.6 (2 x CHAr), 133.8, 136.5, 136.9, 138.5, 
141.3, 142.0, 161.0; MS: m/z (%) 474 (M
+, 72), 383 (17), 330 (100), 182 (82). Anal. Calcd for 
C28H30N2OS2: C, 70.85; H, 6.37; N, 5.90. Found: C, 70.82; H, 6.32; N, 5.84. 
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4.4.2.  5-[(Z)-1-(4-chlorophenyl)methylidene]-2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,5,6,7-  
tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5b):  
 
 
Yield 67%, Yellow solid  m.p. 167-169 
oC; IR (KBr): ν 3062, 2965, 1698, 1617, 1477, 687 cm
-1; 
1H 
NMR (DMSO-d6): δ
 0.93 (s, 6H, CH3), 1.20-1.25 (d, J = 6.7 Hz, 3H, CH3), 1.52-1.55 (quasi d, J = 4.6 
Hz, 2H, CH2), 2.07 (s, 2H, CH2), 2.35 (s, 3H, CH3), 2.62-2.65 (m, 1H, CH), 6.68 (s, 1H, CH-S), 7.20 
(d, J = 7.8 Hz, 2H, ArH), 7.55-7.60 (m, 6H, ArH), 7.80 (s, 1H, CH=C); 
13C NMR (DMSO-d6): δ 18.5, 
22.7, 26.8, 29.1 (2 x CH3), 36.7, 42.1, 45.7, 71.8, 126.3 (2 x CHAr), 127.0, 127.6, 128.9 (2 x CHAr), 
129.1, 130.3 (2 x CHAr), 132.8 (2 x CHAr), 133.8, 134.3, 136.5, 138.5, 141.3, 142.0, 161.0; MS: m/z 
495 (M
+). Anal. Calcd for C27H27ClN2OS2: C, 65.50; H, 5.50; N, 5.66. Found: C, 65.44; H, 5.48; N, 
5.60. 
 
 
4.4.3.  2-(4-methylphenyl)-5-[(Z)-1-(4-nitrophenyl)methylidene]-3-(5,5,7-trimethyl-4,5,6,7-  
tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5c):  
 
 
Yield 70%, Brown solid m.p. 192-194 
oC; IR (KBr): ν 3067, 2962, 1699, 1612, 1542, 1477, 1371 cm
-
1; 
1H NMR (DMSO-d6): δ
 0.92 (s, 6H, CH3), 1.21-1.25 (d, J = 6.7 Hz, 3H, CH3), 1.54-1.57 (quasi d, J 
= 4.6 Hz, 2H, CH2), 2.10 (s, 2H, CH2), 2.38 (s, 3H, CH3), 2.61-2.66 (m, 1H, CH), 6.62 (s, 1H, CH-S), 
7.10-7.20 (m, 6H, ArH), 7.72 (s, 1H, CH=C), 8.12 (d, J = 8.3 Hz, 2H, ArH); 
13C NMR (DMSO-d6): δ 
18.5, 22.7, 26.8, 29.1 (2 x CH3), 36.7, 42.1, 45.7, 71.8, 125.6, 126.3 (2 x CHAr), 127.0, 128.9 (2 x 
CHAr), 130.1, 130.9 (2 x CHAr), 133.8 (2 x CHAr), 136.5, 138.5, 141.3, 142.0, 142.8, 146.8, 161.0; 
MS: m/z 505 (M
+). Anal. Calcd for C27H27N3O3S2: C, 64.14; H, 5.38; N, 8.31. Found: C, 64.11; H, 
5.32; N, 8.28. 
 
 
4.4.4.  2-(4-methylphenyl)-5-[(Z)-1-(3-nitrophenyl)methylidene]-3-(5,5,7-trimethyl-4,5,6,7- 
tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5d):  
 
 
Yield 66%, Pale brown solid m.p. 183-185 
oC; IR (KBr): ν 3069, 2972, 1694, 1614, 1541, 1477, 1374 
cm
-1; 
1H NMR (DMSO-d6): δ
 0.96 (s, 6H, CH3), 1.20-1.25 (d, J = 6.7 Hz, 3H, CH3), 1.54-1.56 (quasi 
d, J = 4.6 Hz, 2H, CH2), 2.10 (s, 2H, CH2), 2.38 (s, 3H, CH3), 2.60-2.65 (m, 1H, CH), 6.62 (s, 1H, 
CH-S), 7.10-7.20 (m, 4H, ArH), 7.80-7.90 (m, 4H, ArH), 8.26 (s, 1H, ArH); 
13C NMR (DMSO-d6): δ 
18.5, 22.7, 26.8, 29.1 (2 x CH3), 36.7, 42.1, 45.7, 71.8, 121.8, 126.3 (2 x CHAr), 126.7, 127.0 (2 x 
CHAr), 128.9 , 131.3, 132.1, 133.8, 135.1, 135.8, 136.5, 138.5, 141.3, 142.0, 152.4, 161.0; MS: m/z       Biologically active compounds containing linked thiazolyl-thiazolidinone heterocycles 
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505 (M
+). Anal. Calcd for C27H27N3O3S2: C, 64.14; H, 5.38; N, 8.31. Found: C, 64.12; H, 5.34; N, 
8.26. 
 
 
4.4.5.  5-[(Z)-1-(4-hydroxyphenyl)methylidene]-2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,  5,6,7-
tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5e):  
N
S
N
S
CH3
O
OH
 
 
Yield 67%, Pale yellow solid m.p. 163-164 
oC; IR (KBr): ν 3342-3210, 3071, 2975, 1695, 1616, 1478 
cm
-1; 
1H NMR (DMSO-d6): δ
 0.94 (s, 6H, CH3), 1.19-.122 (d, J = 6.7 Hz, 3H, CH3), 1.52-1.55 (quasi 
d, J = 4.6 Hz, 2H, CH2), 2.09 (s, 2H, CH2), 2.35 (s, 3H, CH3), 2.60-2.65 (m, 1H, CH), 5.24 (s, 1H, 
OH), 6.62 (s, 1H, CH-S), 6.91 (d, J = 7.8 Hz, 2H, ArH), 7.10-7.20 (m, 6H, ArH), 7.72 (s, 1H, CH=C); 
13C NMR (DMSO-d6): δ 18.5, 22.7, 26.8, 29.1 (2 x CH3), 36.7, 42.1, 45.7, 71.8, 115.4, 126.3 (2 x 
CHAr), 126.9, 127.0, 128.7 (2 x CHAr), 128.9, 132.3 (2 x CHAr), 133.8 (2 x CHAr), 136.5, 138.5, 
141.3, 142.0, 157.6, 161.0; MS: m/z 476 (M
+). Anal. Calcd for C27H28N2O2S2: C, 68.04; H, 5.92; N, 
5.88. Found: C, 68.00; H, 5.87; N, 5.81. 
 
4.4.6.  5-[(Z)-1-(2-hydroxyphenyl)methylidene]-2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,5,  6,7-
tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5f):  
N
S
N
S
CH3
O
HO
 
 
Yield 66%, Pink solid m.p. 171-173 
oC; IR (KBr): ν 3345-3250, 3077, 2972, 1699, 1612, 1479 cm
-1; 
1H NMR (DMSO-d6): δ
 0.96 (s, 6H, CH3), 1.20-1.25 (d, J = 6.7 Hz, 3H, CH3), 1.55-1.60 (quasi d, J = 
4.6 Hz, 2H, CH2), 2.11 (s, 2H, CH2), 2.37 (s, 3H, CH3), 2.61-2.64 (m, 1H, CH), 4.60 (s, 1H, OH), 6.62 
(s, 1H, CH-S), 7.10-7.20 (m, 8H, ArH), 7.80 (s, 1H, CH=C); 
13C NMR (DMSO-d6): δ 18.5, 22.7, 26.8, 
29.1 (2 x CH3), 36.7, 42.1, 45.7, 71.8, 116.4, 118.7, 122.9, 126.3 (2 x CHAr), 127.0, 128.9 (2 x 
CHAr), 130.4, 130.9, 131.4, 133.8, 136.5, 138.5, 141.3, 142.0, 156.8, 161.0; MS: m/z 476 (M
+). Anal. 
Calcd for C27H28N2O2S2: C, 68.04; H, 5.92; N, 5.88. Found: C, 68.02; H, 5.88; N, 5.84. 
 
4.4.7.  5-(Z)-1-[4-(dimethylamino)phenyl]methylidene-2-(4-methylphenyl)-3-(5,5,7-trimethyl- 
4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5g):  
 
 
Yield 64%, Pale red solid m.p. 184-186 
oC; IR (KBr): ν 3068, 2978, 1698, 1616, 1478 cm
-1; 
1H NMR 
(DMSO-d6): δ
 0.91 (s, 6H, CH3), 1.22-1.25 (d, J = 6.7 Hz, 3H, CH3), 1.52-1.55 (quasi d, J = 4.6 Hz, 
2H, CH2), 2.09 (s, 2H, CH2), 2.35 (s, 3H, CH3), 2.60-2.65 (m, 1H, CH), 2.98 (s, 6H, N-CH3), 6.62 (s, 
1H, CH-S), 6.70-6.80 (m, 4H, ArH), 7.10-7.20 (m, 4H, ArH), 7.69 (s, 1H, CH=C); 
13C NMR (DMSO-
d6): δ 18.5, 22.7, 26.8, 29.1 (2 x CH3), 36.7 (2 x CH3), 38.4, 42.1, 45.7, 71.8, 114.5, 120.4, 126.3 (2 x 
CHAr), 127.0, 128.3 (2 x CHAr), 128.9, 132.1 (2 x CHAr), 133.8 (2 x CHAr), 136.5, 138.5, 141.3, Nagaraj et al., Org. Commun. (2012) 5:4 160-170 
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142.0, 151.7, 161.0; MS: m/z 504 (M
+ + 1). Anal. Calcd for C29H33N3OS2: C, 69.15; H, 6.60; N, 8.34. 
Found: C, 69.12; H, 6.58; N, 8.30. 
 
 
4.4.8.  5-[(Z)-1-(4-hydroxy-3-methoxyphenyl)methylidene]-2-(4-methylphenyl)-3-(5,5,7-
trimethyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5h):  
 
 
Yield 69%, Orange solid m.p. 155-157 
oC; IR (KBr): ν 3340-3250, 3070, 2978, 1698, 1616, 1478, 
1270 cm
-1; 
1H NMR (DMSO-d6): δ
 0.94 (s, 6H, CH3), 1.19-1.22 (d, J = 6.7 Hz, 3H, CH3), 1.52-1.55 
(quasi d, J = 4.6 Hz, 2H, CH2), 2.09 (s, 2H, CH2), 2.35 (s, 3H, CH3), 2.60-2.65 (m, 1H, CH), 3.76 (s, 
3H, OCH3), 5.21 (s, 1H, OH), 6.62 (s, 1H, CH-S), 6.70-6.80 (m, 4H, ArH), 7.10-7.20 (m, 4H, ArH), 
7.63 (s, 1H, CH=C); 
13C NMR (DMSO-d6): δ 18.5, 22.7, 26.8, 29.1 (2 x CH3), 36.7, 42.1, 45.7, 57.3, 
71.8, 114.2, 115.7, 126.3 (2 x CHAr), 127.0, 127.3, 127.6, 128.9 (2 x CHAr), 132.3, 133.8, 136.5, 
138.5, 141.3, 142.0, 147.3, 148.1, 161.0; MS: m/z 506 (M
+). Anal. Calcd for C28H30N2O3S2: C, 66.38; 
H, 5.97; N, 5.53. Found: C, 66.32; H, 5.94; N, 5.49. 
 
4.4.9.  5-[(Z)-1-(2-furyl)methylidene]-2-(4-methylphenyl)-3-(5,5,7-trimethyl-4,5,6,7-tetra-  hydro-
1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5i):  
 
 
Yield 71%, Black solid  m.p. 172-174 
oC; IR (KBr): ν 3068, 2978, 1698, 1616, 1478, 1030 cm
-1; 
1H 
NMR (DMSO-d6): δ
 0.94 (s, 6H, CH3), 1.19 -1.22 (d, J = 6.7 Hz, 3H, CH3), 1.52-1.55 (quasi d, J = 4.6 
Hz, 2H, CH2), 2.09 (s, 2H, CH2), 2.35 (s, 3H, CH3), 2.60-2.65 (m, 1H, CH), 6.10-6.20 (m, 2H, ArH), 
6.62 (s, 1H, CH-S), 7.10-7.20 (m, 5H, ArH), 7.90 (s, 1H, CH=C); 
13C NMR (DMSO-d6): δ 18.5, 22.7, 
26.8, 29.1 (2 x CH3), 36.7, 42.1, 45.7, 71.8, 110.2, 121.4, 126.3 (2 x CHAr), 127.0 , 128.9(2 x CHAr), 
133.8, 136.5, 136.9, 138.5, 141.3, 142.0, 146.7, 153.4, 161.0; MS: m/z 450 (M
+). Anal. Calcd for 
C25H26N2O2S2: C, 66.64; H, 5.82; N, 6.22. Found: C, 66.61; H, 5.80; N, 6.14. 
 
4.4.10.  2-(4-methylphenyl)-5-[(Z)-1-(2-thienyl)methylidene]-3-(5,5,7-trimethyl-4,5,6,7-tetra- 
hydro-1,3-benzothiazol-2-yl)-1,3-thiazolan-4-one (5j):  
 
 
Yield 72%, Black solid m.p. 159-161 
oC; IR (KBr): ν 3062, 2946, 1694, 1612, 1479, 957 cm
-1; 
1H 
NMR (DMSO-d6): δ
 0.94 (s, 6H, CH3), 1.19-1.22 (d, J = 6.7 Hz, 3H, CH3), 1.52-1.55 (quasi d, J = 4.6 
Hz, CH2), 2.09 (s, 2H, CH2), 2.35 (s, 3H, CH3), 2.60-2.65 (m, 1H, CH), 6.60-6.70 (m, 3H, ArH, CH-
S), 7.10-7.20 (m, 5H, ArH), 7.91 (s, 1H, CH=C); 
13C NMR (DMSO-d6): δ 18.5, 22.7, 26.8, 29.1 (2 x 
CH3), 36.7, 42.1, 45.7, 71.8, 123.0, 126.3 (2 x CHAr), 127.0, 128.0, 128.9 (2 x CHAr), 129.5, 133.8, 
136.5, 138.5, 141.3, 142.0, 142.8, 150.6, 161.0; MS: m/z 466 (M
+). Anal. Calcd for C25H26N2OS3: C, 
64.34; H, 5.62; N, 6.00. Found: C, 64.30; H, 5.58; N, 5.95.       Biologically active compounds containing linked thiazolyl-thiazolidinone heterocycles 
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